24/7
Buzz
Startups
VC
@work
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
DataTech
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Amgen
Tags search
HOME
24/7
buzz
STARTUPS
VC
Tech@work
Innovation
OPINIONS
EVENTS
ABOUT
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:32
"There are many opportunities for Israeli companies in London"
13:00
Google: “We want to make sure we help Startup Nation dream, build, and grow.”
12:34
Car purchasing in Israel is about to change - here’s how.
12:21
"Permira sees Israel as a strategic target for investments in technology companies"
More stories
Buzz
Most popular
Daily
Weekly
1
Check Point tells employees no raises in 2023
2
High-tech job market in crisis, isn't expected to rebound soon
3
eToro value plummets, raises $250 million at $3.5 valuation
4
Mapping the pioneering Israeli Generative AI startups
5
Creator investment platform Exceed raises $8 million Seed round
More news
Amgen
2 stories about Amgen
Teva Agrees to Stop Selling Amgen Generic Following Patent Infringement Settlement
03.01.19
|
Lilach Baumer
In December, Teva reached a confidential settlement and licensing agreement with drug manufacturer Neos Therapeutics, regarding its generic version for Neos' ADHD drug
Drug Developer Entera Bio Down on Nasdaq Following Amgen Deal
12.12.18
|
Lilach Baumer
The deal, announced Tuesday, could see Entera receive up to $270 million in aggregate payments
Please ensure Javascript is enabled for purposes of
website accessibility